Calcium channel blockers (CCBs) have been used in the treatment of pulmonary hypertension since 1980s (Rubin, 1985). In 1992, a study showed that high doses of CCBs in patients with primary pulmonary hypertension who respond with reductions in pulmonary-artery pressure (PAP) and pulmonary vascular resistance might improve survival over a five-year period (Rich et al., 1992). Subsequently, a number of studies explored the impact of CCBs to the outcome of pulmonary hypertension, especially pulmonary arterial hypertension (PAH). At present, many guidelines suggested that pulmonary vasoreactivity testing should be done in some kinds of pulmonary arterial hypertension and responders are suggested to be treated with high dose CCBs (Galie et al., 2015).

A positive acute response is defined as a reduction of the mean PAP $\geq 10$ mmHg to reach an absolute value of mean PAP $\leq 40$ mmHg with an increased or unchanged cardiac output (Ruopp and Cockrill, 2022). Studies showed that long-term CCBs responders displayed a more pronounced fall in mean PAP and reached an absolute value of mean PAP lower than that measured in non-responders (Sitbon et al., 2005). Whole-exome sequencing showed that gene variants differed in vasodilator-responsive idiopathic PAH versus vasodilator-nonresponsive idiopathic PAH (Hemnes et al., 2016). More biomarkers should be explored to detect vasodilator-responders early and easily, including in other types of pulmonary hypertension (He et al.). The recent research of this Topic showed that TIMP-1 elevation could serve as a circulating biomarker to identify PH among COPD patients.

The recent work highlighted multiple ways to predict the long-term outcome of pulmonary hypertension patients. This Research Topic includes a study which found that besides hemodynamics, exercise capacity was valuable in the evaluation of the long-term...
outcome of pulmonary hypertension patients (Jiang et al.). This recent research showed that exercise-based rehabilitation (aerobic exercise training) may benefit the change from baseline at Week 26 in right ventricular stoke volume (RVSV), determined by pulmonary artery from CMR.

Besides the CCBs that have been predominantly used like diltiazem, nifedipine and amlodipine, other medicine related to calcium signaling have also been used in pulmonary hypertension (Humbert et al., 2022). Levosimendan, a calcium sensitizing agent with positive inotropic and vasodilatory effects, holds promise for patients with pulmonary hypertension and right heart failure (Hoepner and Granton, 2011; Coz Yataco et al., 2016) (Qu et al.). This recent research showed that Levosimendan treatment could effectively improve acute decompensated right heart failure and systemic hemodynamics in connective tissue disease-associated pulmonary arterial hypertension patients, with positive effects on survival in hospital.

Many gene mutations are involved in the etiology of pulmonary hypertension such as BMPR2. In this topic, we reported a rare case of pulmonary hypertension caused by Kartagener’s syndrome with a novel homozygous nonsense mutation in CCDC40 gene (Dai et al.). This finding expanded the mutational spectra of CCDC40 gene related Kartagener’s syndrome which is vital for screening and genetic diagnosis of the disease.

Calcium is involved in the etiology, mechanism and therapy target in pulmonary hypertension. CCBs can be used in first diagnosed pulmonary arterial hypertension and calcium sensitizing agent can be used in the late-stage pulmonary hypertension with right heart failure. More researches should be investigated in the future, such as: whether CCBs can be used in other types of pulmonary hypertension? are there calcium signaling related gene mutation or biomarkers are related to pulmonary hypertension? whether new drugs can be developed targeting calcium signaling such as calcium channels or calcium related receptors?

**Author contributions**

J-FL organized this topic and write this editorial.

**Funding**

This work is supported by National Natural Science Foundation of China (82270051). Reform and Development Program of Beijing Institute of Respiratory Medicine (ysrhl2022006).

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.